Drug name - Envarsus Xr

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617599 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8623410 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8586084 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US9763920 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8591946 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US7994214 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8486993 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US9161907 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8889186 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8623411 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US10548880 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8889185 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US9757362 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US10166190 VELOXIS PHARMS INC Stabilized tacrolimus composition May, 2028

(5 years from now)

US11123331 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients May, 2028

(5 years from now)

US11110081 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients May, 2028

(5 years from now)

US10864199 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients May, 2028

(5 years from now)

US9549918 VELOXIS PHARMS INC Stabilized tacrolimus composition May, 2028

(5 years from now)

US8685998 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients Aug, 2028

(5 years from now)

US8664239 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients Aug, 2028

(5 years from now)

Drugs and Companies using TACROLIMUS ingredient

Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; prophylaxis of organ rejection in de novo transplant patient; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient; Prophylaxis of organ rejection in de novo transplant patient; prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection; prophylaxis of organ rejection in de novo transplant patient; prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection; prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.75MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 4MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.